{"id":"CHEMBL104829","canonicalSmiles":"CN(Cc1coc2nc(N)nc(N)c12)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1","inchiKey":"WXINNGCGSCFUCR-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FURO[2,3D]PYRIMIDINE ANTIFOLATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02026"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1068","canonicalSmiles":"NC(=O)N1c2ccccc2CC(=O)c2ccccc21","inchiKey":"CTRLABGOLIVAIY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXCARBAZEPINE","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Oxcarbazepine","Oxtellar xr","Trileptal"],"synonyms":["GP-47680","KIN-493","NSC-758693","Oxcarbamazepine","Oxcarbazepine","SPN-804"],"crossReferences":{"DailyMed":["oxcarbazepine"],"PubChem":["144204534","170464811","174006287","26719673","26747194","50085868","866068"],"Wikipedia":["Oxcarbazepine"],"drugbank":["DB00776"],"chEBI":["7824"]},"linkedTargets":{"rows":["ENSG00000185313","ENSG00000153253","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000196876"],"count":10},"linkedDiseases":{"rows":["EFO_0005762","MONDO_0005090","EFO_1001219","EFO_0004216","HP_0000726","EFO_0003015","HP_0001250","EFO_0000311","HP_0000713","EFO_0000474","EFO_0000289","MONDO_0002050","MONDO_0005301","EFO_0004263","MONDO_0004979","EFO_0005230"],"count":16},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for epilepsy and seizure and has 10 investigational indications."}
{"id":"CHEMBL110971","canonicalSmiles":"CCCCCCCCC(O)(P(=O)(O)O)P(=O)(O)O","inchiKey":"COHUUYPEYRMWTH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL110971","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06931"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1161789","canonicalSmiles":"O=S(=O)(O)CCCSc1nc2ccccc2s1","inchiKey":"XBNHRNFODJOFRU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1161789","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03132"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1180003","canonicalSmiles":"CCCCCCCCCCCCCC[N+](C)(C)C","inchiKey":"GLFDLEXFOHUASB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CETRIMIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Cetrimide"],"crossReferences":{"PubChem":["29217879"]},"childChemblIds":["CHEMBL325636","CHEMBL113150","CHEMBL109747"],"description":"Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL1200562","canonicalSmiles":"CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C","inchiKey":"FZCHYNWYXKICIO-FZNHGJLXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYDROCORTISONE VALERATE","yearOfFirstApproval":1978,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Hydrocortisone valerate","Westcort"],"synonyms":["Cortisol 17-valerate","Hydrocortisone 17-valerate","Hydrocortisone valerate","NSC-759133"],"crossReferences":{"DailyMed":["hydrocortisone%20valerate"],"PubChem":["144204404","170464775","56422095","855996"],"drugbank":["DB14544"],"chEBI":["50865"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_0009552","EFO_0005752","HP_0004798"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for eye inflammation and hemorrhoid."}
{"id":"CHEMBL1200644","canonicalSmiles":"CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]","inchiKey":"XEKSTYNIJLDDAZ-JASSWCPGSA-D","drugType":"Oligosaccharide","blackBoxWarning":true,"name":"FONDAPARINUX SODIUM","yearOfFirstApproval":2001,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201202","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Arixtra","Fondaparinux sodium"],"synonyms":["Fondaparin sodium","Fondaparinux sodium","Fondaparinux sodium for assay","Fondaparinux sodium identification","IC-851589","ORG 31540","ORG-31540","Quixidar","SR 90107A","SR-90107A"],"crossReferences":{"DailyMed":["fondaparinux%20sodium"]},"linkedTargets":{"rows":["ENSG00000117601"],"count":1},"linkedDiseases":{"rows":["HP_0001907","HP_0000083","EFO_0003827","EFO_0004286","EFO_0003907","HP_0004936"],"count":6},"description":"Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201153","canonicalSmiles":"CCC(NC(C)C)C(O)c1ccc(O)c(O)c1.CS(=O)(=O)O","inchiKey":"SOYAGMVKMXZVNZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ISOETHARINE MESYLATE","yearOfFirstApproval":1984,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201213","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bronchilator","Bronkometer","Isoetharine mesylate"],"synonyms":["Isoetarine mesilate","Isoetharine mesilate","Isoetharine mesylate","NSC-759286"],"crossReferences":{"PubChem":["144204319","50106482","56422893","85231307","856022"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984."}
{"id":"CHEMBL1201244","canonicalSmiles":"C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1","inchiKey":"YXRDKMPIGHSVRX-OOJCLDBCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ROCURONIUM","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Rocuronium","Rocuronium cation","Rocuronium ion"],"crossReferences":{"DailyMed":["rocuronium%20bromide"],"PubChem":["50112687"],"Wikipedia":["Rocuronium_bromide"],"drugbank":["DB00728"],"chEBI":["8884"]},"childChemblIds":["CHEMBL1200648"],"linkedTargets":{"rows":["ENSG00000170175","ENSG00000138435","ENSG00000135902","ENSG00000108556","ENSG00000196811"],"count":5},"linkedDiseases":{"rows":["MONDO_0018373","EFO_0003086","MONDO_0021117","EFO_1000637","MONDO_0001187","EFO_0002950","EFO_0003964","EFO_1000218","EFO_0003931","EFO_0010581","EFO_1001250","EFO_0002618","EFO_0001074","HP_0002093","EFO_0009447","EFO_0005323","EFO_0003832","EFO_0001645","MONDO_0007576","HP_0003418","EFO_0001073","EFO_0003843","MONDO_0008315","EFO_0001422","HP_0003326","HP_0001336","MONDO_0005178","HP_0000023","EFO_0009492","HP_0003470"],"count":30},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 9 investigational indications."}
{"id":"CHEMBL121941","canonicalSmiles":"NC(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1","inchiKey":"RUUOIINPNMNPIU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL121941","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08241"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231486","canonicalSmiles":"O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1-c1ccc(Br)s1","inchiKey":"IGUZFFOBAZCVRK-VAOFZXAKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1231486","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03804"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1233085","canonicalSmiles":"Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)NP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1","inchiKey":"UQABYHGXWYXDTK-UUOKFMHZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHOSPHOAMINOPHOSPHONIC ACID GUANYLATE ESTER","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02082"],"chEBI":["78408"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234135","canonicalSmiles":"O=C(O)C(=O)CC(=O)c1cccc(N(Cc2ccccc2)Cc2ccccc2)c1","inchiKey":"RMWVENXKUQXLPW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1234135","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08147"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL123904","canonicalSmiles":"Cc1nc2c(O)cccc2c(=O)[nH]1","inchiKey":"YJDAOHJWLUNFLX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NU-1025","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NU-1025"],"crossReferences":{"PubChem":["11114066","525179"],"drugbank":["DB02690"],"chEBI":["75399"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1256137","canonicalSmiles":"Cl.NCCS","inchiKey":"OGMADIBCHLQMIP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CYSTEAMINE HYDROCHLORIDE","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL602","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cystadrops","Cystaran"],"synonyms":["CI-9148","Cysteamine hcl","Cysteamine hydrochloride","Mercaptamine hydrochloride","NSC-21116","NSC-25116","NSC-758692"],"crossReferences":{"DailyMed":["cysteamine%20hydrochloride"],"PubChem":["11533072","144204796","170466795","26747565","50106573","542463"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2012 and is indicated for cystinosis."}
{"id":"CHEMBL1265","canonicalSmiles":"COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2","inchiKey":"LZCDAPDGXCYOEH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ADAPALENE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adapalene","Differin"],"synonyms":["Adapalene","CD 271","CD-271","Differin"],"crossReferences":{"DailyMed":["adapalene"],"PubChem":["144205789","170464674","174006867","26758039"],"Wikipedia":["Adapalene"],"drugbank":["DB00210"],"chEBI":["31174"]},"linkedTargets":{"rows":["ENSG00000131759","ENSG00000077092","ENSG00000172819"],"count":3},"linkedDiseases":{"rows":["MP_0001845","EFO_1002023","EFO_0000701","EFO_0003894"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for acne and has 1 investigational indication."}
{"id":"CHEMBL1294","canonicalSmiles":"C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12","inchiKey":"LOUPRKONTZGTKE-LHHVKLHASA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"QUINIDINE","yearOfFirstApproval":1950,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["(8r,9s)-quinidine",".beta.-quinidine","Conquinine","Kinidin","Pitayine","Quinidine"],"crossReferences":{"DailyMed":["quinidine%20gluconate","quinidine%20sulfate"],"PubChem":["17389531","56320931","56320932"],"drugbank":["DB00908"],"chEBI":["28593"]},"childChemblIds":["CHEMBL2068675","CHEMBL3707183","CHEMBL1435413","CHEMBL1200437","CHEMBL2165709"],"linkedTargets":{"rows":["ENSG00000196876","ENSG00000185313","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000153253"],"count":10},"linkedDiseases":{"rows":["MONDO_0002009","EFO_0004269","EFO_0000275","EFO_0004278","EFO_0003758","EFO_1001249","EFO_1001413","EFO_0004197","MONDO_0005277","MONDO_0002050","MONDO_0005301","EFO_0001068","EFO_0004287","HP_0004308","MONDO_0004975","EFO_0000612","MONDO_0004976","HP_0002019"],"count":18},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL132966","canonicalSmiles":"CNCC/C=C/c1cccnc1","inchiKey":"JUOSGGQXEBBCJB-GORDUTHDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIVANICLINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(e)-metanicotine","Rivanicline","TC-2403","Trans-metanicotine"],"crossReferences":{"PubChem":["26752048"],"drugbank":["DB05855"]},"childChemblIds":["CHEMBL2107367","CHEMBL1783879"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL138806","canonicalSmiles":"O=C(O)C(=O)Nc1sc2c(c1C(=O)O)CCOC2","inchiKey":"SNNOZMNTPOIDSI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL138806","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03102"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL144527","canonicalSmiles":"Fc1ccc(CC2CCNCC2)cc1","inchiKey":"JLAKCHGEEBPDQI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-(4-Fluorobenzyl)Piperidine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-(4-Fluorobenzyl)Piperidine"],"crossReferences":{"drugbank":["DB07110"]},"childChemblIds":["CHEMBL1204355","CHEMBL1802039"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1454910","canonicalSmiles":"O=[N+]([O-])c1ccc(O)c2ncccc12","inchiKey":"RJIWZDNTCBHXAL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NITROXOLINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["A-82","NSC-74947","Nitrohydroxyquinoline","Nitroxoline"],"crossReferences":{"PubChem":["11532939","144205522","170466124","29216358","56423111"],"Wikipedia":["Nitroxoline"],"drugbank":["DB01422"],"chEBI":["67121"]},"childChemblIds":["CHEMBL3251404"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1546","canonicalSmiles":"CC(N)Cc1ccc(O)cc1","inchiKey":"GIKNHHRFLCDOEU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYDROXYAMPHETAMINE","yearOfFirstApproval":1969,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Dl-4-hydroxyamphetamine","Dl-p-hydroxyamphetamine","Hydroxyamfetamine","Hydroxyamphetamine","NSC-170995","Norveritol","P-hydroxyamphetamine","Phenol, p-(2-aminopropyl)-","Pulsoton","Racemic p-hydroxyamphetamine"],"crossReferences":{"DailyMed":["hydroxyamphetamine%20hydrobromide"],"Wikipedia":["Hydroxyamfetamine"],"drugbank":["DB09352"]},"childChemblIds":["CHEMBL1200705"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969."}
{"id":"CHEMBL15511","canonicalSmiles":"CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1","inchiKey":"SPFYMRJSYKOXGV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENROFLOXACIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Baytril"],"synonyms":["BAY VP 2674","Enrofloxacin","Enrofloxacin for veterinary use","NSC-758616"],"crossReferences":{"PubChem":["104171364","144204382","170465572","26746921","50100858","56422205","855596"],"Wikipedia":["Enrofloxacin"],"drugbank":["DB11404"],"chEBI":["35720"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1563","canonicalSmiles":"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl","inchiKey":"GUGHGUXZJWAIAS-QQYBVWGSSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DAUNORUBICIN HYDROCHLORIDE","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL178","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cerubidine","Daunorubicin hydrochloride","Daunoxome"],"synonyms":["Daunorubicin (as hydrochloride)","Daunorubicin hcl","Daunorubicin hydrochloride","FI 6339 HYDROCHLORIDE","FI 6339 [AS THE BASE]","FI-6339","FI-6339 HYDROCHLORIDE","NDC 0082-4155","NDC-0082-4155","NSC-82151","RP 13057 HYDROCHLORIDE","RP 13057 [AS THE BASE)","RP-13057","RP-13057 HYDROCHLORIDE"],"crossReferences":{"DailyMed":["daunorubicin%20hydrochloride"],"PubChem":["144208357","17389073","85273781","855543"]},"linkedTargets":{"rows":["ENSG00000131747"],"count":1},"linkedDiseases":{"rows":["EFO_0003812","EFO_1001945","EFO_0000209","EFO_1001052","MONDO_0003541","EFO_0000565","EFO_0004251","EFO_1001935","EFO_0000330","MONDO_0020743","EFO_0000094","EFO_0000198","EFO_0000221","EFO_0003802","EFO_1001779","EFO_0000220","MONDO_0019457","EFO_0000223","EFO_0000222","EFO_1001946","MONDO_0000870","EFO_0000224","EFO_0003029","EFO_0003025","EFO_0003028","MONDO_0044917","EFO_1001936","EFO_0000574","EFO_1001947","EFO_0000218","EFO_1002001","EFO_0000691","EFO_0003811","EFO_0003027"],"count":34},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 23 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1614702","canonicalSmiles":"COc1cc2c(cc1C(=O)N1CCC(Cc3ccc(F)cc3)CC1)c(C(=O)C(=O)N(C)C)cn2C","inchiKey":"JBNWDYGOTHQHOZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SCIO-323","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SCIO-323","Scio-323"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL163238","canonicalSmiles":"Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2","inchiKey":"BCQTVJKBTWGHCX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PILSICAINIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pilsicainide","Pilsicainide hydrochloride"],"crossReferences":{"PubChem":["144206011","170465988","50112708"],"Wikipedia":["Pilsicainide"],"drugbank":["DB12712"]},"childChemblIds":["CHEMBL4303511"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1676","canonicalSmiles":"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF","inchiKey":"XTULMSXFIHGYFS-VLSRWLAYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUTICASONE FUROATE","yearOfFirstApproval":2007,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Arnuity ellipta","Avamys","Flonase sensimist allergy relief","Relvar ellipta","Trelegy ellipta","Veramyst"],"synonyms":["Allermist","Ennhale","Fluticasone furoate","Furamist","GSK 685 698","GSK-685968","GSK685968","GW-685698X","GW685698X"],"crossReferences":{"DailyMed":["fluticasone%20furoate"],"Wikipedia":["Fluticasone_furoate"],"drugbank":["DB08906"],"chEBI":["74899"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_0005854","HP_0006536","EFO_0008521","EFO_1000391","EFO_0007533","MONDO_0004979","EFO_0000341","EFO_0007141","EFO_1001417","EFO_0003918","EFO_1002029","HP_0001742","EFO_0003956"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 7 approved and 2 investigational indications."}
{"id":"CHEMBL170988","canonicalSmiles":"N=C(N)NC(=N)NCCc1ccccc1","inchiKey":"ICFJFFQQTFMIBG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENFORMIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"," Germany"," France"],"classes":["Metabolism toxicity"],"year":1977},"tradeNames":[],"synonyms":["Phenformin"],"crossReferences":{"PubChem":["11112448","124882390","174006812"],"Wikipedia":["Phenformin"],"drugbank":["DB00914"],"chEBI":["8064"]},"childChemblIds":["CHEMBL2348409","CHEMBL1528839"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diabetes mellitus and has 1 investigational indication. It was withdrawn in United States,  Germany and  France initially in 1977 due to Metabolism toxicity."}
{"id":"CHEMBL1714","canonicalSmiles":"CNC1(c2ccccc2Cl)CCCCC1=O.Cl","inchiKey":"VCMGMSHEPQENPE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"KETAMINE HYDROCHLORIDE","yearOfFirstApproval":1970,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL742","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Anaket-V","Ketalar","Ketamine hydrochloride","Ketanest","Ketavet","Vetalar"],"synonyms":["CI-581","CL 369","CL-369","CN-52,372-2","CN-52372-2","CN-523722","Ketamine (as hydrochloride)","Ketamine hcl","Ketamine hydrochloride","Ketamine hydrochloride ciii","Ketamini hydrochloridum","Special k","Vetalar"],"crossReferences":{"DailyMed":["ketamine%20hydrochloride"],"chEBI":["650657"]},"linkedTargets":{"rows":["ENSG00000161509","ENSG00000273079","ENSG00000116032","ENSG00000183454","ENSG00000105464","ENSG00000176884","ENSG00000198785"],"count":7},"linkedDiseases":{"rows":["EFO_0004320","MONDO_0000726","EFO_0002610","HP_0000989","MONDO_0002009","EFO_0003015","EFO_0004321","HP_0100543","EFO_0003931","MONDO_0002050","EFO_0000289","EFO_0000474","EFO_0003761","MONDO_0007079","EFO_0004215","HP_0000360","HP_0012532","EFO_0009658","EFO_0009963","EFO_1001884","EFO_0003843","EFO_0000311","EFO_0000546","MP_0001914","EFO_0000713","EFO_0007430","EFO_0005611","HP_0030680"],"count":28},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 18 investigational indications."}
{"id":"CHEMBL1724","canonicalSmiles":"C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1.[Br-]","inchiKey":"JRRNZNSGDSFFIR-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"MEPENZOLATE BROMIDE","yearOfFirstApproval":1956,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL524004","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cantil"],"synonyms":["AN-6437","FT-0671006","Glycophenylate","HY-17585","Mepenzolate","Mepenzolate Bromide","Mepenzolate bromide","Mepenzolate methylbromide","Mepenzolone bromide","NSC-4358"],"crossReferences":{"PubChem":["144203918","170465214","26748120","49648464"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."}
{"id":"CHEMBL1742999","drugType":"Antibody","blackBoxWarning":false,"name":"CARLUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CNTO 888","CNTO-888","Carlumab"],"linkedTargets":{"rows":["ENSG00000108691"],"count":1},"linkedDiseases":{"rows":["MONDO_0008315","EFO_0009448","EFO_0000311"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1743000","drugType":"Antibody","blackBoxWarning":false,"name":"CITATUZUMAB BOGATOX","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Citatuzumab bogatox","VB6-845"],"linkedTargets":{"rows":["ENSG00000119888"],"count":1},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1908360","canonicalSmiles":"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C","inchiKey":"HKVAMNSJSFKALM-GKUWKFKPSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"EVEROLIMUS","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Afinitor","Afinitor disperz","Certican","Votubia","Zortress"],"synonyms":["40-o-(2-hydroxyethyl)-rapamycin","Everolimus","RAD 666","RAD-001","RAD-666","RAD001","SDZ-RAD","Sdz rad"],"crossReferences":{"DailyMed":["everolimus"],"PubChem":["144206063"],"drugbank":["DB01590"],"chEBI":["68478"]},"linkedTargets":{"rows":["ENSG00000088832"],"count":1},"linkedDiseases":{"rows":["EFO_1000256","EFO_0000637","EFO_0000365","EFO_0000558","EFO_0000681","EFO_0005952","Orphanet_306498","Orphanet_141127","EFO_0000632","EFO_1001951","EFO_1000634","MONDO_0022529","EFO_0000588","EFO_0000339","MONDO_0002974","MONDO_0008903","EFO_0003884","MONDO_0020732","MONDO_0015277","EFO_1000882","Orphanet_2495","EFO_0000514","EFO_0000760","EFO_1000312","MONDO_0021054","EFO_0000198","MONDO_0013730","EFO_0002618","MONDO_0002715","Orphanet_636","EFO_1001968","MONDO_0004986","EFO_1001496","MONDO_0008315","EFO_0005221","EFO_1000026","EFO_0000630","MONDO_0002691","EFO_1001231","Orphanet_398934","MONDO_0020290","MONDO_0021639","Orphanet_2869","EFO_0000574","EFO_0001378","EFO_0001376","EFO_0005672","EFO_0001062","EFO_0003086","EFO_0001365","EFO_0007451","EFO_0002913","MONDO_0007254","EFO_0001071","EFO_0004252","MONDO_0001056","MONDO_0002158","MONDO_0002898","EFO_0004289","EFO_1000630","Orphanet_805","EFO_0000326","EFO_0002499","EFO_0000183","MONDO_0003478","EFO_0000616","EFO_0003897","EFO_0005220","EFO_0006859","EFO_1000601","EFO_0007331","EFO_0002916","MONDO_0024503","EFO_0001645","EFO_0000403","Orphanet_44890","EFO_0000222","MONDO_0007576","EFO_0004599","EFO_0003896","MONDO_0002120","MONDO_0002603","EFO_0000764","MONDO_0011962","EFO_0000702","MONDO_0002367","EFO_1000852","EFO_0000763","EFO_1001927","MONDO_0024880","EFO_0000519","EFO_0003869","MONDO_0000873","EFO_0003046","EFO_0000228","EFO_0000540","EFO_0000333","EFO_0003913","EFO_0000565","EFO_0000544","HP_0001871","MONDO_0003268","EFO_0000389","EFO_0000182","MONDO_0005411","Orphanet_637","EFO_1000045","EFO_0009441","MONDO_0000447","EFO_0008620","EFO_0000220","MONDO_0002108","EFO_0004224","MONDO_0008170","EFO_0000349","Orphanet_3389","EFO_0009708","EFO_0005537","EFO_0006544","MONDO_0021640","MONDO_0009348","EFO_0002970","MONDO_0100342","EFO_1001901","EFO_1001469","MONDO_0021063","MONDO_0002087","Orphanet_538","EFO_0000305","EFO_1002048","EFO_0000272","EFO_0000231","MONDO_0001187","HP_0000083","EFO_1001480","EFO_1000218","EFO_0000474","EFO_1000044","MONDO_0041161","EFO_0003860","EFO_0000770","EFO_0002626","Orphanet_93460","EFO_0003047","EFO_0002617","EFO_1000158","EFO_1000616","MONDO_0016586","EFO_0000313","EFO_0004243","HP_0009720","EFO_0003060","EFO_0000311","EFO_0003863","MONDO_0016693","EFO_0006861","EFO_0003833","EFO_0000691","MONDO_0021637","EFO_0000181","MONDO_0001422"],"count":161},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 19 approved and 115 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1963685","drugType":"Unknown","blackBoxWarning":false,"name":"LUCINACTANT","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Surfaxin"],"synonyms":["ATI 02","ATI-02","KL4-SURFACTANT","Kl-surfactant","Lucinactant"],"crossReferences":{"DrugCentral":["4232"]},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 5 investigational indications."}
{"id":"CHEMBL203567","canonicalSmiles":"Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1","inchiKey":"IJDQETGUEUJVTB-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RO-3201195","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ro-3201195","SYD003","Syd-003"],"crossReferences":{"drugbank":["DB08424"],"chEBI":["45116"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2042273","canonicalSmiles":"COC(=O)[C@H](c1ccccc1Cl)N1CCc2sc(OC(C)=O)cc2C1","inchiKey":"GNHHCBSBCDGWND-KRWDZBQOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VICAGREL","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Vicagrel"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2103802","canonicalSmiles":"CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1.C[C@H](O)CO.O","inchiKey":"GOADIQFWSVMMRJ-UPGAGZFNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DAPAGLIFLOZIN PROPYLENE GLYCOL","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL429910","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Farxiga"],"synonyms":["BMS-512148-05","Dapagliflozin","Dapagliflozin propanediol","Dapagliflozin propylene glycol"],"crossReferences":{"chEBI":["85079"]},"linkedTargets":{"rows":["ENSG00000140675"],"count":1},"linkedDiseases":{"rows":["EFO_0003144","MONDO_0005147","MONDO_0005148"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for heart failure and type 2 diabetes mellitus and has 1 investigational indication."}
{"id":"CHEMBL2103815","canonicalSmiles":"CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C","inchiKey":"NYGCNONRVCGHAT-UFIKZEAMSA-N","drugType":"Protein","blackBoxWarning":false,"name":"LARAZOTIDE ACETATE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL2105646","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AT-1001","AT-1001 (LARAZOTIDE ACETATE)","Larazotide acetate"],"linkedTargets":{"rows":["ENSG00000117971","ENSG00000080644"],"count":2},"linkedDiseases":{"rows":["EFO_0001060"],"count":1},"description":"Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2103879","canonicalSmiles":"CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O","inchiKey":"RVAQIUULWULRNW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GANETESPIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ganetespib","STA 9090","STA-9090"],"crossReferences":{"drugbank":["DB12047"]},"linkedTargets":{"rows":["ENSG00000080824","ENSG00000096384"],"count":2},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","EFO_0002916","MONDO_0015686","EFO_0000756","MONDO_0008170","EFO_0000571","Orphanet_44890","MONDO_0007254","EFO_1000657","EFO_0000222","MONDO_0021063","EFO_0003060","MONDO_0001056","MONDO_0002158","EFO_1000044","EFO_0003968","EFO_0006861","EFO_0000770","EFO_0005537","EFO_0000182","MONDO_0008903","EFO_0000702","EFO_0000673","MONDO_0003219","EFO_0001378","EFO_0000760"],"count":27},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 23 investigational indications."}
{"id":"CHEMBL2108086","drugType":"Unknown","blackBoxWarning":false,"name":"SULODEXIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sulodexide","Vessel due f"],"crossReferences":{"DrugCentral":["4726"]},"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL2108183","drugType":"Small molecule","blackBoxWarning":false,"name":"CRILANOMER","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Crilanomer"],"crossReferences":{"DrugCentral":["4854"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2108568","drugType":"Protein","blackBoxWarning":false,"name":"TREBANANIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG 386","AMG-386","Tovasanib","Trebananib"],"linkedTargets":{"rows":["ENSG00000091879","ENSG00000154188"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0015686","EFO_0000681","MONDO_0008170","EFO_1001465","MONDO_0007254","MONDO_0002087","EFO_0003060","EFO_0000632","MONDO_0002158","EFO_1000218","EFO_0003968","EFO_0000182","EFO_0008528","EFO_0000673","EFO_1000158"],"count":16},"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."}
{"id":"CHEMBL2108676","drugType":"Enzyme","blackBoxWarning":true,"name":"ELOSULFASE ALFA","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bmn 110, rhgalns, n-acetylgalactosamine-6-sulfatase, chondroitinsulfatase, galactose-6-sulfate sulfatase, ec=3.1.6.4","Vimizim"],"synonyms":["BMN 110","BMN-110","Chondroitin sulfatase","Chondroitinase","Chondrosulfatase","E.c. 3.1.6.4","Elosulfase alfa","RHGALNS"],"crossReferences":{"DailyMed":["elosulfase%20alfa"],"DrugCentral":["4999"]},"description":"Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2109249","drugType":"Antibody","blackBoxWarning":false,"name":"AMG-557","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG-557","Amg-557","MEDI-5872","Medi 5872","Prezalumab"],"linkedTargets":{"rows":["ENSG00000160223"],"count":1},"linkedDiseases":{"rows":["EFO_0003834","EFO_0002690","EFO_0000676","EFO_0000699"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2109354","drugType":"Antibody","blackBoxWarning":false,"name":"MONO-DGA-RFB4","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MONO-DGA-RFB4","Mono-dga-rfb4"],"linkedTargets":{"rows":["ENSG00000012124"],"count":1},"linkedDiseases":{"rows":["EFO_0000574"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109481","drugType":"Antibody","blackBoxWarning":false,"name":"ICM3","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ICM3"],"description":"Antibody drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2109536","drugType":"Antibody","blackBoxWarning":false,"name":"KB-001","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Humaneered"],"synonyms":["KB-001","Kb-001"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109569","drugType":"Antibody","blackBoxWarning":false,"name":"AUROGRAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Aurograb"],"synonyms":["Aurograb"],"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2109621","drugType":"Antibody","blackBoxWarning":false,"name":"ABITUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ALD403","Abituzumab","DI 17E6","DI-17E6","DI17E6","EMD 525797","EMD-525797"],"linkedTargets":{"rows":["ENSG00000138448"],"count":1},"linkedDiseases":{"rows":["EFO_1001480","MONDO_0008170","EFO_0004244","EFO_0000717","MONDO_0008315","EFO_1001951"],"count":6},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2110579","canonicalSmiles":"CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1","inchiKey":"VQPFSIRUEPQQPP-MXBOTTGLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANAMORELIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anamorelin","RC-1291","ST-1291"],"crossReferences":{"drugbank":["DB06645"]},"childChemblIds":["CHEMBL2103794"],"linkedTargets":{"rows":["ENSG00000121853"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","HP_0004326","HP_0012378","EFO_0003060"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2110602","canonicalSmiles":"CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CC#N)[C@H]2SC1","inchiKey":"RRYMAQUWDLIUPV-BXKDBHETSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEPHACETRILE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cefacetrile","Vetrimast"],"crossReferences":{"drugbank":["DB01414"]},"childChemblIds":["CHEMBL2104099"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL213490","canonicalSmiles":"O=P(O)(O)C(O)(Cc1cccc(-c2cccc(-c3ccccc3)c2)c1)P(=O)(O)O","inchiKey":"YXQQNSYZOQHKHD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(1-Hydroxy-1-Phosphono-2-[1,1';3',1'']Terphenyl-3-Yl-Ethyl)-Phosphonic Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(1-Hydroxy-1-Phosphono-2-[1,1';3',1'']Terphenyl-3-Yl-Ethyl)-Phosphonic Acid"],"crossReferences":{"drugbank":["DB07404"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2140942","canonicalSmiles":"COc1ccc2[nH]cc(CCN(C(C)C)C(C)C)c2c1","inchiKey":"DNBPMBJFRRVTSJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2140942","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["124954085"],"drugbank":["DB01441"],"chEBI":["48282"]},"childChemblIds":["CHEMBL2357882"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2160007","canonicalSmiles":"CCOc1nc(N)nc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(OC(C)C)O[C@H]2[C@@]1(C)F","inchiKey":"PVRFQJIRERYGTQ-UYISCHNFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PSI-352938","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-0938","GS0938","Gs-0938","PSI-352938","PSI-938","PSI352938","PSI938","Psi-352938"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL217914","canonicalSmiles":"C[C@@H](C(=O)N1CCOCC1)N1CC[C@H](NS(=O)(=O)c2cc3ccc(Cl)cc3s2)C1=O","inchiKey":"PHLKBODTBJLXRD-WFASDCNBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL217914","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07844"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL221118","canonicalSmiles":"Nc1cccc(CCc2ccc3cc[nH]c3c2)n1","inchiKey":"OSHSZKRWKLQZBV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL221118","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07206"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL232201","canonicalSmiles":"CCc1oc2ccccc2c1C(=O)c1cc(I)c(O)c(I)c1","inchiKey":"CZCHIEJNWPNBDE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BENZIODARONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," France"],"classes":["Hepatotoxicity"],"year":1964},"tradeNames":[],"synonyms":["Amplivix","Benziodarone","L 2329","L-2329","NSC-82133"],"crossReferences":{"PubChem":["144205346","170465852","29216089"],"TG-GATEs":["130"],"Wikipedia":["Benziodarone"],"drugbank":["DB13277"]},"linkedTargets":{"rows":["ENSG00000198668"],"count":1},"linkedDiseases":{"rows":["EFO_0000319"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in United Kingdom and  France initially in 1964 due to Hepatotoxicity."}
{"id":"CHEMBL232557","canonicalSmiles":"Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1","inchiKey":"CEXBEGBNDJVZPK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL232557","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07024"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2326966","canonicalSmiles":"N=C(N)NCCC[C@H](NC(=O)CCC(=O)OC[N+]1(c2cc(=O)c3cccc(-c4ccccc4)c3o2)CCOCC1)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)[O-]","inchiKey":"SVNJBEMPMKWDCO-KCHLEUMXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SF-1126","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SF 1126","SF-1126","SF-1126 INNER SALT","Sf-1126"],"linkedTargets":{"rows":["ENSG00000145675","ENSG00000171608","ENSG00000105647","ENSG00000141506","ENSG00000051382","ENSG00000121879","ENSG00000105851","ENSG00000117461","ENSG00000198793"],"count":9},"linkedDiseases":{"rows":["EFO_0000182","EFO_0000181","EFO_0000621","EFO_0000311"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL23330","canonicalSmiles":"NC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-]","inchiKey":"WOCXQMCIOTUMJV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRETAZICAR","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CB-1954","NSC-115829","Tretazicar"],"crossReferences":{"PubChem":["11110923","17404763","411933","46500339","50105941","50105942","85230965","90341816"],"drugbank":["DB04253"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL236687","canonicalSmiles":"C=C(C)[C@@H]1CC=C(CO)CC1","inchiKey":"NDTYTMIUWGWIMO-SNVBAGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PERILLYL ALCOHOL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dihydrocuminic alcohol","Dl-perillyl alcohol","FEMA NO. 2664","Hydrocumin alcohol","Iso-carveol","NSC-641066","Perillol","Perillyl alcohol"],"crossReferences":{"PubChem":["500472","93576954"],"drugbank":["DB15289"],"chEBI":["10782"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL244888","canonicalSmiles":"O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1ccc(O)cc1","inchiKey":"YCWSUKQGVSGXJO-NTUHNPAUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NIFUROXAZIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ercefuryl 200"],"synonyms":["NSC-759261","Nifuroxazide","RC-27109","SJ000287313"],"crossReferences":{"Wikipedia":["Nifuroxazide"],"drugbank":["DB13855"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL245678","canonicalSmiles":"CN1CCc2nc(C(=O)N[C@@H]3CCCC[C@@H]3NC(=O)c3cc4cc(Cl)ccc4[nH]3)sc2C1","inchiKey":"ARPFWVKYXJZULB-DLBZAZTESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL245678","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07629"]},"childChemblIds":["CHEMBL556396"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL24828","canonicalSmiles":"COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1","inchiKey":"UHTHHESEBZOYNR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"VANDETANIB","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Caprelsa","Zactima"],"synonyms":["GNF-PF-2188","NSC-744325","NSC-760766","Vandetanib","ZD-64","ZD-6474","ZD6474"],"crossReferences":{"DailyMed":["vandetanib"],"PubChem":["103905338","124893338","144206064","170465617","50100123","50112766"],"Wikipedia":["Vandetanib"],"drugbank":["DB05294"],"chEBI":["49960"]},"childChemblIds":["CHEMBL533849"],"linkedTargets":{"rows":["ENSG00000128052","ENSG00000165731","ENSG00000106123","ENSG00000065361","ENSG00000037280","ENSG00000120156","ENSG00000146904","ENSG00000135333","ENSG00000178568","ENSG00000142627","ENSG00000196411","ENSG00000044524","ENSG00000116106","ENSG00000101213","ENSG00000146648","ENSG00000102755","ENSG00000070886","ENSG00000080224","ENSG00000182580","ENSG00000145242","ENSG00000183317","ENSG00000141736","ENSG00000154928","ENSG00000197122","ENSG00000133216"],"count":25},"linkedDiseases":{"rows":["EFO_0003869","EFO_0000365","MONDO_0100342","MONDO_0004192","EFO_1001465","MONDO_0007254","EFO_1000657","MONDO_0002087","MONDO_0020654","EFO_1001951","MONDO_0001187","MONDO_0001056","MONDO_0002158","EFO_0000588","MONDO_0008903","MONDO_0044710","EFO_0000182","EFO_0000501","EFO_0000641","MONDO_0015277","EFO_0002499","EFO_1000158","EFO_0002618","EFO_0000616","EFO_0003897","EFO_0006859","EFO_0002916","MONDO_0002108","MONDO_0008170","EFO_0000349","Orphanet_44890","EFO_0000222","EFO_0002501","EFO_0007535","MONDO_0008627","EFO_0003060","MONDO_0008315","EFO_0000621","EFO_0000311","EFO_0009708","EFO_1000026","EFO_0000630","EFO_0001663","EFO_1000489","EFO_0003841","EFO_0002892","EFO_0000702","MONDO_0002367","EFO_0006544","MONDO_0003219","EFO_0001378","MONDO_0024880","EFO_0000519","MONDO_0021637","EFO_0000181"],"count":55},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 7 approved and 41 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL267044","canonicalSmiles":"CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC","inchiKey":"BGRJTUBHPOOWDU-NSHDSACASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVOSULPIRIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(-)-sulpiride","L-sulpiride","Lesuride","Levobren","Levopraid","Levopride","Levosulpiride","S-(-)-sulpiride","Sulpiride l-form","Sulpiride, (-)-","Sulpiride, (s)-"],"crossReferences":{"PubChem":["11112626","11113767","170465834","26719874","50104627"],"Wikipedia":["Levosulpiride"],"chEBI":["64119"]},"linkedTargets":{"rows":["ENSG00000149295","ENSG00000164270"],"count":2},"linkedDiseases":{"rows":["HP_0000713","EFO_0005407","EFO_0009321","EFO_0008533"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL281593","canonicalSmiles":"N=C(N)NCC(=O)O","inchiKey":"BPMFZUMJYQTVII-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GUANIDINO ACETATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Guanidinoacetic Acid"],"crossReferences":{"Wikipedia":["Glycocyamine"],"drugbank":["DB02751"],"chEBI":["16344"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL304383","canonicalSmiles":"CNCC(=O)O","inchiKey":"FSYKKLYZXJSNPZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SARCOSINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Methylamino-Acetic Acid","Sarcosine"],"crossReferences":{"PubChem":["57264366"],"Wikipedia":["Sarcosine"],"drugbank":["DB12519"],"chEBI":["15611"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3233142","canonicalSmiles":"CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12.Cc1ccc(S(=O)(=O)O)cc1","inchiKey":"LHAPOGAFBLSJJQ-GUTACTQSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LUMATEPERONE TOSYLATE","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3306803","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Caplyta"],"synonyms":["ITI-007 tosylate","Lumateperone tosylate"],"crossReferences":{"DailyMed":["lumateperone%20tosylate"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for schizophrenia."}
{"id":"CHEMBL3301676","canonicalSmiles":"CC(=O)O.C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2","inchiKey":"KWFNVZFWXXEJKL-YZDVLOIKSA-N","drugType":"Protein","blackBoxWarning":false,"name":"LINACLOTIDE ACETATE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL3301675","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Linaclotide acetate","MD-1100 ACETATE","MM-416775"],"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL34076","canonicalSmiles":"Nc1[nH]c(=O)[nH]c(=O)c1N","inchiKey":"BBTNLADSUVOPPN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL34076","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03826"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545117","drugType":"Small molecule","blackBoxWarning":false,"name":"AVE-9940","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ave-9940"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545237","canonicalSmiles":"C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C","inchiKey":"CKAXZOYFIHQCBN-UQOAMHMYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HE3235","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Apotone"],"synonyms":["Apoptone","HE-3235","He 3235","He3235"],"linkedTargets":{"rows":["ENSG00000169083"],"count":1},"linkedDiseases":{"rows":["MONDO_0008315"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545254","canonicalSmiles":"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=NO)CC[C@]4(C)[C@H]3CC[C@@]21C","inchiKey":"QNTASHOAVRSLMD-GYKMGIIDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OLESOXIME","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-cholest-en-3-one, oxime","Cholest-4-en-3-one, oxime","NSC-21311","Olesoxime","TRO-19622","TRO19622"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL3707247","canonicalSmiles":"CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N","inchiKey":"XRVDGNKRPOAQTN-FQEVSTJZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OZANIMOD","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Ozanimod","RPC-1063","RPC1063"],"crossReferences":{"DailyMed":["ozanimod%20hydrochloride"],"drugbank":["DB12612"]},"childChemblIds":["CHEMBL3707246"],"linkedTargets":{"rows":["ENSG00000170989"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","MONDO_0100096","MONDO_0005301","EFO_0001421","EFO_0000540","EFO_0000384"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for immune system disease and multiple sclerosis and has 5 investigational indications."}
{"id":"CHEMBL3707378","drugType":"Small molecule","blackBoxWarning":false,"name":"CB-189625","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CB-625","Cb-189625"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3707386","drugType":"Small molecule","blackBoxWarning":false,"name":"FERROUS TARTRATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ferrous tartrate","Ferrum tartaricum","Iron tartrate (fe(c4h4o6))"],"crossReferences":{"DrugCentral":["4545"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3833301","canonicalSmiles":"CCC1(c2ccccc2)C(=O)NC(=O)NC1=O.CNC(C)CC1CCCCC1","inchiKey":"MJCBWPMBFCUHBP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BARBEXACLONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Maliasin"],"synonyms":["Barbexaclone"],"crossReferences":{"DrugCentral":["4345"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for epilepsy."}
{"id":"CHEMBL383705","canonicalSmiles":"CC(C)[C@H](N)C(=O)N1CCCC1","inchiKey":"IHBAVXVTGLANPI-QMMMGPOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL383705","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01884"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3989529","canonicalSmiles":"CCCCCCCC/C=C\\CCCCCCCC(=O)O.NCCO","inchiKey":"KGWDUNBJIMUFAP-KVVVOXFISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHANOLAMINE OLEATE","yearOfFirstApproval":1988,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ethamolin"],"synonyms":["Ethanolamine oleate","NSC-760382"],"crossReferences":{"DailyMed":["ethanolamine%20oleate"],"drugbank":["DB06689"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988 and is indicated for esophageal varices."}
{"id":"CHEMBL3989892","canonicalSmiles":"OCCN1CCN(CCC=C2c3ccccc3Sc3ccc(Cl)cc32)CC1","inchiKey":"WFPIAZLQTJBIFN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLOPENTHIXOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB13841"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3989917","canonicalSmiles":"Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1","inchiKey":"HZIYEEMJNBKMJH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FOSNETUPITANT","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["07-PNET","Fosnetupitant"],"crossReferences":{"DailyMed":["fosnetupitant%20chloride%20hydrochloride"],"drugbank":["DB14019"]},"childChemblIds":["CHEMBL3989919"],"linkedTargets":{"rows":["ENSG00000115353"],"count":1},"linkedDiseases":{"rows":["EFO_0006911","HP_0002013"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for chemotherapy-induced nausea and vomiting and vomiting."}
{"id":"CHEMBL4086143","canonicalSmiles":"O=C1CC(c2c[nH]c3ccc(F)cc23)C(=O)N1","inchiKey":"MXKLDYKORJEOPR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-06840003","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF-06840003","Pf-06840003"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL419380","canonicalSmiles":"O=C(OCCN1CCCCCC1)C(c1ccsc1)C1CCCCC1","inchiKey":"MMNICIJVQJJHHF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CETIEDIL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cetiedil"],"crossReferences":{"drugbank":["DB13753"],"chEBI":["34619"]},"childChemblIds":["CHEMBL1968477","CHEMBL2112496"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297253","canonicalSmiles":"COc1nc(C(Cl)(Cl)Cl)c(Cl)c(OC(=O)O[C@H]2CC[C@@]3(C)C(=CC[C@@H]4[C@@H]3CC[C@@]3(C)[C@H]4CC[C@@H]3[C@H](C)CCCC(C)C)C2)c1Cl","inchiKey":"ZJUUIXYKTPSIOH-LEZJFEBPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-demethyl-4-cholesteryloxycarbonylpenclomedine","Dm-choc-pen","Mipicoledine"],"crossReferences":{"drugbank":["DB15075"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297285","drugType":"Small molecule","blackBoxWarning":false,"name":"HEME ARGINATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Haem arginate","Heme arginate"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4297306","canonicalSmiles":"CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C","inchiKey":"PHEWVCZHSBTZFX-DBCSJUPNSA-N","drugType":"Protein","blackBoxWarning":false,"name":"NBI-6024","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nbi-6024"],"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297477","canonicalSmiles":"Cn1cc(Nc2nccc(N3C[C@@H]4CC[C@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1","inchiKey":"BUWBRTXGQRBBHG-MJBXVCDLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BREPOCITINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Brepocitinib","PF-06700841","Pf-06700841"],"crossReferences":{"drugbank":["DB15003"]},"childChemblIds":["CHEMBL4298160"],"linkedTargets":{"rows":["ENSG00000162434","ENSG00000105397"],"count":2},"linkedDiseases":{"rows":["EFO_1002028","EFO_0003086","EFO_0000729","EFO_0004192","EFO_1000710","EFO_0002690","EFO_0003778","EFO_0000676","EFO_0000274","EFO_0000384"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL4297575","drugType":"Antibody","blackBoxWarning":false,"name":"NIRSEVIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MED-18897","MEDI8897","Medi8897","Nirsevimab"],"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297873","drugType":"Unknown","blackBoxWarning":false,"name":"ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Advate","Antihemophilic factor, human recombinant","BAY 14-2222","BAY 81-8973","BAY W 6240","BAY-14-2222","BAY-81-8973","BAY-W-6240","BAY81-8973","Bay81-8973","Factor viii octocog alfa","Factor viii, recombinant","Octocog alfa"],"description":"Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4298075","drugType":"Small molecule","blackBoxWarning":false,"name":"PROPOLIS WAX","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bee propolis","Fengjiao","Propolis","Propolis cera","Propolis wax"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL4302507","canonicalSmiles":"[Cs]","inchiKey":"TVFDJXOCXUVLDH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CESIUM","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL4297365"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL435191","canonicalSmiles":"O=C1c2c(c3c4ccc(O)cc4n([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c3[nH]c4cc(O)ccc4c23)C(=O)N1NC(CO)CO","inchiKey":"QMVPQBFHUJZJCS-NTKFZFFISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EDOTECARIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Edotecarin","J-107088","PF-804950"],"crossReferences":{"drugbank":["DB04882"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL440498","canonicalSmiles":"O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1","inchiKey":"ROSNVSQTEGHUKU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CTS-1027","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cts-1027","RO-1130830","RS-130830"],"crossReferences":{"drugbank":["DB08490"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4435170","canonicalSmiles":"[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC","inchiKey":"BZZKEPGENYLQSC-FIBGUPNXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEUCRAVACITINIB","maximumClinicalTrialPhase":3,"parentId":"CHEMBL4596392","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-986165","Bms-986165","Deucravacitinib"],"linkedTargets":{"rows":["ENSG00000105397"],"count":1},"linkedDiseases":{"rows":["EFO_0003834","EFO_0000729","EFO_0003086","EFO_0005761","EFO_0002690","MONDO_0004670","HP_0001410","EFO_0000676","EFO_0003778","EFO_0000540"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL444144","canonicalSmiles":"COCCO","inchiKey":"XNWFRZJHXBZDAG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2-METHOXYETHANOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Methoxyethanol"],"crossReferences":{"PubChem":["144211397","68096"],"Wikipedia":["2-Methoxyethanol"],"drugbank":["DB02806"],"chEBI":["46790"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL448500","canonicalSmiles":"OCCc1ccccc1","inchiKey":"WRMNZCZEMHIOCP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENYLETHYL ALCOHOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".beta.-(hydroxyethyl)benzene","FEMA NO. 2858","NSC-406252","Phenethanol","Phenethyl alcohol","Phenylethanol","Phenylethyl alcohol"],"crossReferences":{"PubChem":["144207093","144208520","144213695","170466787","29217973","47193693"],"Wikipedia":["Phenethyl_alcohol"],"drugbank":["DB02192"],"chEBI":["49000"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594248","canonicalSmiles":"CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O)C(C)C","inchiKey":"LDVRMNJZLWXJPL-JKQNMTHDSA-N","drugType":"Protein","blackBoxWarning":false,"name":"CALCITONIN HUMAN","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cibacalcin"],"synonyms":["Calcitonin (human synthetic)","Calcitonin human"],"linkedTargets":{"rows":["ENSG00000004948"],"count":1},"linkedDiseases":{"rows":["EFO_0005754"],"count":1},"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for parathyroid disease."}
{"id":"CHEMBL4594436","canonicalSmiles":"Cc1cc([N+](=O)[O-])c(NS(=O)(=O)c2cccc(C(=O)O)c2)cc1-c1cccnc1","inchiKey":"QUQGQIASFYWKAB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALOFANIB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alofanib"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594477","drugType":"Unknown","blackBoxWarning":false,"name":"IMA-026","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ima-026"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594547","drugType":"Antibody","blackBoxWarning":false,"name":"TEMELIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GNBAC1","Gnbac1","Temelimab"],"linkedTargets":{"rows":["ENSG00000242950"],"count":1},"linkedDiseases":{"rows":["MONDO_0005301","MONDO_0005147","EFO_0003929"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4594611","drugType":"Antibody","blackBoxWarning":false,"name":"PATRITUMAB DERUXTECAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Patritumab deruxtecan","U3 1402","U3-1402","U3-1402A"],"linkedTargets":{"rows":["ENSG00000065361","ENSG00000198900"],"count":2},"linkedDiseases":{"rows":["EFO_1001480","MONDO_0007254","EFO_0003060"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4650321","canonicalSmiles":"C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1","inchiKey":"MZPVEMOYADUARK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ORELABRUTINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Innobruka"],"synonyms":["ICP-022","Icp-022","Orelabrutinib"],"linkedTargets":{"rows":["ENSG00000010671"],"count":1},"linkedDiseases":{"rows":["EFO_0009441","EFO_0007160","EFO_0000096","EFO_0002690","EFO_0000095","MONDO_0044887","EFO_0000403","EFO_1000157","EFO_0003929","MONDO_0018906","EFO_1001469","EFO_0000183","EFO_0000311"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL4650365","canonicalSmiles":"C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F","inchiKey":"WDHOIABIERMLGY-CMJOXMDJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CAMIZESTRANT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZ-14066724","AZ14066724","AZD-9833","AZD9833","Azd9833","Camizestrant"],"linkedTargets":{"rows":["ENSG00000091831"],"count":1},"linkedDiseases":{"rows":["MONDO_0007254"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4650387","drugType":"Protein","blackBoxWarning":false,"name":"CDX-301","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Amg-949","CDX-301","Cdx 301","Cdx-301"],"linkedTargets":{"rows":["ENSG00000122025"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","EFO_0006859","MONDO_0015686","EFO_0000756","EFO_0000681","MONDO_0008170","EFO_0000403","MONDO_0007254","MONDO_0007576","EFO_1001469","MONDO_0008315","EFO_0005221","EFO_0003060","EFO_1001951","MONDO_0001056","EFO_1000044","MONDO_0002158","EFO_0000182","EFO_0000574","EFO_0006544","EFO_0002617"],"count":21},"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications."}
{"id":"CHEMBL4650414","drugType":"Unknown","blackBoxWarning":false,"name":"ONO-7475","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ONO-7475","Ono-7475"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4650440","drugType":"Unknown","blackBoxWarning":false,"name":"RG-7795","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ana-773","Ana773","RG7795","Rg-7795"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4650463","canonicalSmiles":"[2H][C@@](N)(CO)C(=O)O","inchiKey":"MTCFGRXMJLQNBG-LIIDHCAMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEUTARSERINE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL285123","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["C-21692","CTP-692","Ctp-692","Deutarserine"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4650468","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"BEPIROVIRSEN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bepirovirsen","GSK-3228836","GSK-3228836B","GSK3228836","GSK3228836B","Gsk3228836","IONIS HBVRX","ISIS-505358","ISIS-GSK3RX"],"description":"Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4802192","drugType":"Unknown","blackBoxWarning":false,"name":"ZAPNOMETINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ATR-002","Atr-002","PD-0184264","Zapnometinib"],"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4802239","canonicalSmiles":"C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C.O=C(O)CCC(=O)O","inchiKey":"YXYAEUMTJQGKHS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MOBOCERTINIB SUCCINATE","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL4650319","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Exkivity"],"synonyms":["Mobocertinib succinate"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for non-small cell lung carcinoma. This drug has a black box warning from the FDA."}
{"id":"CHEMBL556","canonicalSmiles":"CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN","inchiKey":"UBQYURCVBFRUQT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEFEROXAMINE","yearOfFirstApproval":1968,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Deferoxamine","Desferal","Desferoxamine b","Desferrioxamine","Desferrioxamine b","Dfo-b","NSC-527604"],"crossReferences":{"DailyMed":["deferoxamine%20mesylate"],"PubChem":["93577020"],"Wikipedia":["Deferoxamine"],"drugbank":["DB00746"],"chEBI":["4356"]},"childChemblIds":["CHEMBL2002581","CHEMBL1234"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 12 investigational indications."}
{"id":"CHEMBL572879","canonicalSmiles":"Nc1ccc(N)c2c1C(=O)c1c(O)ccc(O)c1C2=O","inchiKey":"QVEMRPAUHFWHRV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL572879","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03924"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL62836","canonicalSmiles":"CC(C)COc1cccc(-c2nc3cc(C(=N)N)c(F)cc3[nH]2)c1O","inchiKey":"NSUDDASMRZSVON-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL62836","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06855"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL64894","canonicalSmiles":"CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-]","inchiKey":"ZXJXZNDDNMQXFV-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"GENTIAN VIOLET","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL459265","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["GV 11","Genapax","Methylrosaniline Cl","Methylrosanilinium Cl","Pyoktanin","Viocid"],"synonyms":["Basic violet 1","Basic violet 3","C.i. 42535","C.i. basic violet 1","C.i. basic violet 3","Ci 42535","Crystal violet","GNF-Pf-880","Gentian violet","Lowacryl violet 1","Methyl violet","Methyl violet 10b","Methylrosaniline chloride","Methylrosanilinii chloridum","Methylrosanilinium chloride","NSC-3090"],"crossReferences":{"PubChem":["144204635","144208960","144210888","170464787","17389869","26748060","26752909","538591"],"Wikipedia":["Crystal_violet","Methyl_violet"],"chEBI":["41688"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications."}
{"id":"CHEMBL74074","canonicalSmiles":"O=P(O)(O)OCCCc1c[nH]c2ccccc12","inchiKey":"NKEZSFZOUIIZFL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL74074","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03171"],"chEBI":["28162"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL896","canonicalSmiles":"OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1","inchiKey":"ZQDWXGKKHFNSQK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYDROXYZINE","yearOfFirstApproval":1956,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Atarax","Ataraxoid","Hydroxyzine","Marex","NSC-169188","Orgatrax","Tran-q","Tranquizine","U.c.b-4492"],"crossReferences":{"DailyMed":["hydroxyzine%20hydrochloride","hydroxyzine%20pamoate"],"PubChem":["144207118","170464958"],"TG-GATEs":["71"],"Wikipedia":["Hydroxyzine"],"drugbank":["DB00557"],"chEBI":["5818"]},"childChemblIds":["CHEMBL1201007","CHEMBL3186993","CHEMBL1200467"],"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0005531","HP_0000989","MONDO_0002050","EFO_0006788","EFO_0003819","HP_0000726","EFO_0000701","EFO_0004257","EFO_0005230","EFO_0003843"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 6 approved and 3 investigational indications."}
{"id":"CHEMBL98123","canonicalSmiles":"COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC.Cl","inchiKey":"UOTMYNBWXDUBNX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PAPAVERINE HYDROCHLORIDE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL19224","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Papaver hcl","Pavabid"],"synonyms":["Artegodan","Cardoverina","NSC-35443","Papaverine hcl","Papaverine hydrochloride","Papaverini hydrochloridum","Vasorin"],"crossReferences":{"PubChem":["144203777","170465687","26747626","50106832","544606","56422444","855961"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL998","canonicalSmiles":"CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1","inchiKey":"JCCNYMKQOSZNPW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LORATADINE","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alavert","Children's claritin","Claritin","Claritin hives relief","Claritin hives relief reditab","Claritin reditabs","Clarityn","Clarityn rapide","Clarityne","Hay-rite","Loratadine","Loratadine redidose","Roletra"],"synonyms":["BAY76-2211","Claritin-D","Loratadine","NSC-758628","SCH 29851","SCH-29851"],"crossReferences":{"DailyMed":["loratadine"],"PubChem":["104171183","11111394","11113345","124880597","124880599","144203736","144211849","170464867","26719690","26747010","26751528","50104102","535878","56424146","85231118","855843","90340694"],"Wikipedia":["Loratadine"],"drugbank":["DB00455"]},"childChemblIds":["CHEMBL4092143"],"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0005854","EFO_0008521","EFO_0000685","HP_0000989","MONDO_0007254","MONDO_0005271","EFO_0009658","HP_0003418","Orphanet_538","EFO_0000274","EFO_0004232","EFO_0005531","MONDO_0100096","MONDO_0005301","HP_0002653","EFO_0000574","MONDO_0004979","EFO_0007141","EFO_0001378","EFO_1001417","EFO_0003956"],"count":21},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 9 investigational indications."}
